GlassScriptPhysician profile
Vinod Kondragunta
NPI 1588906168
$2,817.78
in general payments reported to CMS, 2019-2025
29 companies · $408 in 2025
The $408 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2021: $11.92 · 2022: $18.89 · 2023: $893 · 2024: $1,259 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,475 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,475.03 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $582.36 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $309.47 | 2023-2025 | Alunbrig, Iclusig, Fruzaqla |
| Gilead Sciences, INC. | $258.08 | 2021-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $212.36 | 2019-2025 | Imfinzi, Tagrisso |
| Pfizer INC. | $182.37 | 2023-2024 | |
| Celgene Corporation | $151.15 | 2023-2024 | Reblozyl, Pomalyst |
| Tersera Therapeutics LLC | $150.83 | 2023-2025 | Zoladex, Xermelo |
| Genzyme Corporation | $125.00 | 2019 | |
| Merck Sharp & Dohme LLC | $111.92 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $107.38 | 2023-2024 | Enhertu |
| Incyte Corporation | $104.29 | 2023-2024 | Jakafi, Monjuvi |
| Ipsen Biopharmaceuticals, INC | $70.89 | 2024 | Onivyde |
| Bayer Healthcare Pharmaceuticals INC. | $54.59 | 2023-2025 | |
| Emd Serono, INC. | $49.04 | 2024 | |
| Genentech USA, INC. | $43.10 | 2023 | Alecensa, Tecentriq, Lunsumio |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $30.99 | 2023 | |
| Abbvie INC. | $28.99 | 2024 | |
| Beigene USA, INC. | $27.00 | 2023 | Brukinsa |
| Jazz Pharmaceuticals INC. | $26.97 | 2024 | |
| G1 Therapeutics, INC. | $22.65 | 2023 | Cosela |
| Sobi, INC | $22.30 | 2025 | |
| Tempus Ai, INC | $20.66 | 2024 | |
| Servier Pharmaceuticals LLC | $19.91 | 2024 | |
| Cti Biopharma Corp. | $19.74 | 2023 | Vonjo |
| E.R. Squibb & Sons, L.L.C. | $19.59 | 2024 | Eliquis |
| Fresenius Kabi USA, LLC | $16.83 | 2025 | Stimufend |
| Dova Pharmaceuticals | $16.79 | 2019 | |
| Amgen INC. | $16.42 | 2023 | Evenity, Prolia |
| Morphosys, US INC. | $16.11 | 2023 | Monjuvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinod Kondragunta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.